# Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

> **NCT03731832** · PHASE2 · COMPLETED · sponsor: **GWT-TUD GmbH** · enrollment: 66 (actual)

## Conditions studied

- Refractory Multiple Myeloma

## Interventions

- **DRUG:** MLN9708
- **DRUG:** Pomalidomide 4 MG Oral Capsule
- **DRUG:** Dexamethasone
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03731832
- **Lead sponsor:** GWT-TUD GmbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-20
- **Primary completion:** 2024-04-22
- **Final completion:** 2024-04-22
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03731832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03731832, "Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT03731832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*